Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06906562 · ClinicalTrials.gov registry record · Phase 2
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
A Phase 2 study of Stage IV Pancreatic Cancer AJCC v8 and Stage III Pancreatic Cancer AJCC v8, sponsored by Sameek Roychowdhury.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 20
- Study locations
NCT06906562: Recruiting Phase 2 study of Stage IV Pancreatic Cancer AJCC v8 and Stage III Pancreatic Cancer AJCC v8, sponsored by Sameek Roychowdhury.
NCT06906562 is a Phase 2 study of Stage IV Pancreatic Cancer AJCC v8 and Stage III Pancreatic Cancer AJCC v8 that is actively recruiting participants, run by Sameek Roychowdhury. The registered enrollment target is 40 participants, below the 87-participant average among 31 other Stage IV Pancreatic Cancer AJCC v8 trials with a reported enrollment target (54% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06906562, a Phase 2 study of Stage IV Pancreatic Cancer AJCC v8 and Stage III Pancreatic Cancer AJCC v8, is actively recruiting participants, sponsored by Sameek Roychowdhury.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II study evaluates how well pemigatinib works for the treatment of adult patients with pancreatic cancer that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or has spread from where it first started to other places in the body (metastatic) and that have abnormal changes (alterations) in the fibroblast growth factor receptor (FGFR) gene. FGFR genes are genes that, when altered, can lead to and promote the growth of cancer in patients. Researchers want to test if using pemigatinib can block the function of these abnormal FGFR genes and prevent the tumor from growing and whether treatment can help improve overall quality of life.
Primary Outcome
The proportion of patients with a best overall response of complete response (CR) or partial response (PR). Overall response rate assessed per RECIST v1.1. Will be evaluated in all patients who received at least 80% of the recommended dose of pemigatinib averaged over a 9-week period. ORR will be calculated along with its 95% confidence interval
Conditions Studied
Interventions
- PROCEDURE Magnetic Resonance Imaging
- PROCEDURE Bone Scan
- PROCEDURE Computed Tomography (CT)
- DRUG Pemigatinib
- PROCEDURE Optical Coherence Tomography
Study Locations (20)
California
- Ohio State University Telemedicine - Fresno
- Ohio State University-Telemedicine - Los Angeles
- Ohio State University-Telemedicine - San Diego
- Ohio State University-Telemedicine - San Francisco
Colorado
- Ohio State University-Telemedicine - Aurora
- Ohio State University Telemedicine - Denver
- Ohio State University Telemedicine - Durango
- Ohio State University Telemedicine - Grand Junction
Alabama
- Ohio State University-Telemedicine - Birmingham
- Ohio State University-Telemedicine - Mobile
- Ohio State University Telemedicine - Montgomery
Arizona
- Ohio State University Telemedicine - Flagstaff
- Ohio State University-Telemedicine - Phoenix
- Ohio State University-Telemedicine - Tucson
Alaska
- Ohio State University-Telemedicine - Anchorage
Arkansas
- Ohio State University-Telemedicine - Hot Springs
Connecticut
- Ohio State University-Telemedicine - New Haven
Delaware
- Ohio State University-Telemedicine - Wilmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-08-26 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 2 |
What NCT06906562 shows while recruiting
NCT06906562 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 87-participant average among 31 other Stage IV Pancreatic Cancer AJCC v8 trials with a reported enrollment target (54% lower).
The record links to 5 conditions, with Stage IV Pancreatic Cancer AJCC v8 appearing as the primary indexed condition, and to 5 interventions - of which Magnetic Resonance Imaging is the first listed.
NCT06906562 names 20 study sites across 10 states, led by California, Colorado, Alabama.
Frequently Asked Questions
What is clinical trial NCT06906562 about?
NCT06906562 is a clinical study titled "A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations". This phase II study evaluates how well pemigatinib works for the treatment of adult patients with pancreatic cancer that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or has spread from where it first started to other places in the body...
What is the current status of trial NCT06906562?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-08-26. Estimated completion is 2028-12-31.
What conditions does trial NCT06906562 study?
This clinical trial studies the following conditions: Stage IV Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8, Metastatic Pancreatic Carcinoma, Advanced Pancreatic Carcinoma.
What interventions are being tested in trial NCT06906562?
The interventions under investigation include: Magnetic Resonance Imaging (PROCEDURE), Bone Scan (PROCEDURE), Computed Tomography (CT) (PROCEDURE), Pemigatinib (DRUG), Optical Coherence Tomography (PROCEDURE).
Who is sponsoring clinical trial NCT06906562?
This trial is sponsored by Sameek Roychowdhury, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06906562 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Pancreatic Cancer AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06906562's enrollment target sits among peer trials
40 16th of 31 higher than 15 of 31 other Stage IV Pancreatic Cancer AJCC v8 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stage IV Pancreatic Cancer AJCC v8 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer
RECRUITING · Phase 2
-
Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis
RECRUITING · Phase 2
-
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI